All Awards Company Events Invest Partners

Nov 26, 2021

Wiseed crowdfunding

Oct 29, 2021

101 Best France Medical Device Startups

Sep 24, 2021

Dianosic at the ERS congress 2021

Jul 08, 2021

What are the main causes of epistaxis?

Apr 19, 2021

Snitem – Dianosic receives the public’s favorite award 2021

Sep 21, 2020

Marc Augustin: B SMART Interview

Let's connect

Need more information?

Contact

DIANOSIC

Biotech · Paris & Strasbourg · Founded 2017

Reinventing drug delivery via the intranasal route

Dianosic develops complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

Key highlights

Cutting-edge platform of intranasal, long-acting solid dosage forms

The DIAXX insert delivers a targeted, low dose of drug in a controlled manner for up to 12 months.

Significant potential across respiratory and neurological indications

Chronic allergic rhinitis (8M), chronic rhinosinusitis (5M) and CNS diseases via Nose-to-Brain delivery (Schizophrenia, Parkinson — 23M) represent large adressable markets.

Solving a critical adherence challenge

50% of patients do not adhere to their medications across therapeutic areas. Our "insert and forget" approach guarantees 100% adherence.

€7M raised in 2025 — led by Aptar Pharma

Series A round with Aptar (Global drug delivery leader), Noshaq, Capital Grand Est and Finovam Gestion to accelerate clinical development.

A complementary team

In-house Pharma and Medtech expertise supported by a Scientific Board composed of world-renowned experts.

contact@dianosic.com